Comments
Dr. Reddy’s Laboratories has acquired 6.46 per cent of the shareholding of Edity Therapeutics Ltd, an Israel-based development stage biotechnology company. As part of the acquisition, Hyderabad-based Dr. Reddy’s acquired 1,014,442 preferred A-1 shares of Edity on a fully diluted basis for a cash consideration, by way of conversion of Simple Agreement for Future Equity investment of $2 million to Preferred A-1 shares. The shares were acquired at $1.9715 per Preferred A-1 share.
Edity is an Israeli development stage biotechnology company focussing on a breakthrough platform technology for intracellular delivery of therapeutic proteins utilising immune cells. Therapeutics based on the Edity technology could be useful in multiple therapeutic areas, including gene editing, rare genetic disorders, oncology and inflammation. Edity has not yet commercialised its technology/products and, hence, does not generate any revenues.
“The funds invested by Dr. Reddy’s will be utilised by Edity to further develop its technology platform. This includes performing pre-clinical studies for safety and efficacy evaluation, securing intellectual property through patent filings, and exploring licensing opportunities, collaborations, and market entry strategies to optimize the commercial viability of Edity’s technology platform,’‘ the company informed the BSE on Friday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.